Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway - Takeaways - MDSpire

Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway

  • By

  • Jiayu You

  • Qianshuo Liu

  • Xingqiang Li

  • April 30, 2026

  • 0 min

Share

  • 1

    The monoclonal antibody 7B8 significantly reduces cerebral Aβ deposition and improves cognitive function in APP/PS1 mice.

  • 2

    7B8 treatment does not increase the risk of microhemorrhage compared to IgG controls in young APP/PS1 mice.

  • 3

    7B8 preserves blood-brain barrier integrity by enhancing endothelial cell function and reducing perivascular Aβ40 deposition.

  • 4

    The antibody modulates the HMGB-1/RAGE/NF-κB signaling pathway, reducing neuroinflammation markers like IL-6 and TNF-α.

  • 5

    7B8 is a promising candidate for Alzheimer's immunotherapy, offering insights into minimizing amyloid-related imaging abnormalities.

Original Source(s)

Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway

  • by Jiayu You, Qianshuo Liu, Xingqiang Li

  • April 30, 2026

Related Content

A new rule puts NIH grant reviewers at risk

Association of high-density lipoprotein cholesterol with the top 10 causes of death

AI-driven insights into protein misfolding and innate immunity in neurodegenerative diseases